Business
Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells
Data is being presented at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting MARLBOROUGH, Mass., May 18, 2023 /PRNewswire/ -- Phio
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"Data is being presented at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting\nMARLBOROUGH, Mass., May 18, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced pre-clinical data demonstrating that using INTASYL to silence TIGIT and CBL-B may be used to improve the anti-tumor response of NK cells, creating a more effective cell therapy for treating cancer.\nLogo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg\nNK cells are the body's first line of defense against cancer. Unlike T cells, NK cells can recognize and kill tumor cells without prior exposure. Incorporating INTASYL's RNAi treatment into ex vivo NK cell expansion protocols prior to adoptive cell therapy (ACT) is a strategy to reduce the expression of inhibitory proteins such as TIGIT or CBL-B to improve anti-tumor response.\n\"These data demonstrate the power of the INTASYL platform to enhance the activity of adoptive cell therapies to better address cancer,\" said James Cardia, Phio's VP of Discovery. \"Furthermore, these studies in addition to recent studies with PH-762 and PH-894, highlight the multiple applications of INTASYL, for both direct therapeutic applications as well as in combination with ACT therapy. INTASYL has the broad applicability to silence not only extracellular targets (TIGIT) but also intracellular targets that antibodies cannot address (CBL-B).\"\nAbout Phio Pharmaceuticals Corp.\nPhio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.\nFor additional information, visit the Company's website, www.phiopharma.com. \nForward Looking Statements\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by word...